Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab.
Hirche
D
D
Rubbert
A
A
Lunau
L
L
Krieg
T
T
Eming
S A
SA
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy*; D009363:Neoplasm Proteins / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000068879:Adalimumab